India’s biotechnology revolution is changing the way the country makes medicines, grows food, manages waste, and protects the environment. In just ten years, India’s bioeconomy has grown from about $10 billion in 2014 to over $130 billion in 2024, and the government now aims to take it to $300 billion by 2030. This growth is not a matter of numbers alone. It shows how science, innovation, and sustainability can work together to create jobs, improve public health, and support the vision of a Viksit Bharat by 2047.
For students preparing for competitive exams or simply following current affairs, this topic is important because it connects policy, economy, health and environment in a single story.
What Is Biotechnology and the Bioeconomy?
Biotechnology means using living organisms, such as bacteria, yeast, plants, and human cells, or their parts to make useful products. Vaccines, antibiotics, biofuels, enzymes and bio-based plastics are all examples.
The bioeconomy is the part of the economy that is built on such biological resources and processes. It includes biopharma, bio-agriculture, bio-industrial products, bio-energy and bio-services. When this economy also reuses waste as a raw material, it is called a circular bioeconomy, and this idea is at the heart of India’s new policy.
The BioE3 Policy: A Major Step Forward
In August 2024, the Union Cabinet, chaired by Prime Minister Narendra Modi, approved the BioE3 Policy. BioE3 stands for Biotechnology for Economy, Environment and Employment. It was prepared by the Department of Biotechnology (DBT) to promote high-performance biomanufacturing, which means producing medicines, materials and chemicals using biological systems instead of traditional chemical methods.
The main objectives of the BioE3 Policy are:
- To speed up India’s shift from chemical-based industries to sustainable, bio-based models.
- To promote a circular bioeconomy, where waste is turned into useful resources.
- To support India’s net-zero carbon goals and the Lifestyle for Environment (LiFE) movement.
- To create bio-foundry clusters, biomanufacturing hubs and Bio-AI hubs.
- To generate jobs, especially in tier-II and tier-III cities, where local biomass can be used as raw material.
It is worth remembering that BioE3 is not India’s first biotechnology initiative. Earlier efforts, such as the National Biotechnology Development Strategy and the National Biopharma Mission, had already laid the groundwork. BioE3 builds on them with a strong focus on manufacturing and sustainability.
Why India Is a Global Biotech Leader
Several strengths place India at the centre of the global biotechnology sector:
- Vaccine capital of the world: India produces about 60% of the world’s vaccines.
- Strong manufacturing base: India has the second-largest number of USFDA-approved manufacturing plants outside the United States.
- Rich biodiversity: The country’s wide range of plants, microbes, and ecosystems offers a valuable base for research and new products.
- Skilled talent and low costs: A large pool of scientists and engineers makes research and production affordable.
Recent Breakthroughs in Indian Biotechnology
Indian scientists and companies have achieved several important milestones in recent years:
- DNA-based COVID-19 vaccine: India developed ZyCoV-D, an indigenous DNA-based vaccine against COVID-19.
- First indigenous HPV vaccine: India developed its first indigenously made vaccine against the human papillomavirus, which causes cervical cancer. It is important to note that this is India’s first indigenous HPV vaccine, not the world’s first.
- Nafithromycin: This is India’s first indigenously discovered antibiotic. It is effective against drug-resistant respiratory infections and is an important step in the fight against antimicrobial resistance.
- Gene therapy for haemophilia: India’s first-in-human gene therapy trial for haemophilia was carried out by BRIC-inStem in collaboration with CMC Vellore. Reported results showed a 60 to 70 percent correction rate with no bleeding episodes, a landmark for Indian medical research.
Startups, Institutions and Collaboration
India now has more than 10,000 biotech startups, compared with only about 50 a decade ago. Many of them work on sustainable products such as bio-based materials, animal-free dairy alternatives and low-cost diagnostics.
The government has also strengthened the ecosystem through several initiatives:
- Mission COVID Suraksha: During the pandemic, the DBT supported vaccine candidates, clinical trial sites and testing facilities, which improved India’s own capabilities.
- Biotechnology Research and Innovation Council (BRIC): This body brings 14 autonomous DBT institutes under one umbrella so that they can work together instead of separately.
- Whole-of-science, whole-of-government, whole-of-nation approach: Researchers, government departments, universities and industry are encouraged to cooperate.
Other Frontier Technologies
India’s ambitions are not limited to biotechnology. The country is investing in other future technologies as well:
- National Quantum Mission: aims to build strong capabilities in quantum computing, communication and sensing.
- Deep Ocean Mission: focuses on exploring and using ocean resources in a sustainable way.
- Anusandhan National Research Foundation (ANRF): created to fund research and bring in strong private sector participation.
- Space programme: Indian astronaut Group Captain Shubhanshu Shukla travelled to the International Space Station in 2025, showing India’s growing role in human spaceflight.
Challenges Ahead
Despite the progress, India must still deal with some challenges. Long-term capital investment is needed for biomanufacturing plants. Clear and quick regulatory approvals are important for new therapies. Cooperation between the Centre and the states must improve, and more skilled workers must be trained in areas such as bioprocessing and bioinformatics. Public trust, ethical standards and biosafety also need constant attention as technologies like gene therapy become more common.
Quick Facts for Exams
- BioE3 Policy: approved by the Union Cabinet in August 2024; full form is Biotechnology for Economy, Environment and Employment.
- Bioeconomy growth: about $10 billion in 2014 to over $130 billion in 2024; target of $300 billion by 2030.
- Vaccines: India produces about 60% of global vaccines.
- BRIC: unites 14 autonomous DBT institutes.
- Nafithromycin: India’s first indigenously discovered antibiotic.
- Gene therapy: first-in-human haemophilia trial by BRIC-inStem and CMC Vellore.
- Key minister: Dr. Jitendra Singh, Union Minister of State (Independent Charge) for Science and Technology.
Conclusion
India’s biotechnology revolution shows how innovation and sustainability can move together. With the BioE3 Policy, a growing startup ecosystem, strong vaccine manufacturing and landmark research in gene therapy and antibiotics, India is moving from being a technology taker to a technology maker. If the country keeps investing in research, skilled people and green manufacturing, the biotechnology sector can become a major driver of economic growth, employment and environmental protection on the way to 2047.
